Juber Pendhari

Making Anti-CD19 CAR-T Cell Therapy Accessible and Affordable: First-in-Human Phase I Clinical Trial Experience from India

Atharva Karulkar, Hasmukh Jain, Shreshtha Shah et al. · Blood · 2022 · 13 citations

Life Sciences, Immunology, Oncology +13

Talicabtagene autoleucel for relapsed or refractory B-cell malignancies: results from an open-label, multicentre, phase 1/2 study

Hasmukh Jain, Atharva Karulkar, Devanshi Kalra et al. · The Lancet Haematology · 2025 · 13 citations

Medicine, Oncology, Immunotherapy +6

High Efficacy and Excellent Safety Profile of Actalycabtagene Autoleucel, a Humanized CD19 CAR-T Product in r/r B-Cell Malignancies: A Phase II Pivotal Trial

Hasmukh Jain, Atharva Karulkar, Devanshi Kalra et al. · Blood · 2023 · 12 citations

Medicine, Oncology, Cell Therapy +12

Novel humanized CD19-CAR-T (Now talicabtagene autoleucel, Tali-cel™) cells in relapsed/ refractory pediatric B-acute lymphoblastic leukemia- an open-label single-arm phase-I/Ib study

Gaurav Narula, Swaminathan Keerthivasagam, Hasmukh Jain et al. · Blood Cancer Journal · 2025 · 10 citations · Full text

Medicine, Immunology, Oncology +17